Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_assertion type Assertion NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_head.
- NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_assertion description "[Both infliximab (chimeric anti-tumor necrosis factor [TNF]-alpha antibody) and etanercept (p75 TNF-alpha receptor/immunoglobulin G fusion protein) are effective against rheumatoid arthritis, but only infliximab induces clinical remission in Crohn's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_provenance.
- NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_assertion evidence source_evidence_literature NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_provenance.
- NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_assertion SIO_000772 15685549 NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_provenance.
- NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_assertion wasDerivedFrom befree-20140225 NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_provenance.
- NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_assertion wasGeneratedBy ECO_0000203 NP935212.RA2orHc4VL6T6mm7FMhZimIJIAC_WyIV06xtX0vrPgG8E130_provenance.